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Amyotrophic lateral sclerosis (ALS) is a debilitating and one of the most common adult-onset neurodegenerative diseases with
the prevalence of about 5 per 100000 individuals. It results in the progressive loss of upper and lower motor neurons and leads to
gradual muscle weakening ultimately causing paralysis and death. ALS has an obscure cause and currently no eﬀective treatment
exists. In this review, a potentially important pathway is described that can be activated by peroxisome proliferator-activated
receptor-γ (PPAR-γ) agonists and has the ability to block the neuropathological damage caused by inﬂammation in ALS and
possibly in other neudegenerative diseases like Huntington’s disease (HD). Neuroinﬂammation is a common pathological feature
in neurodegenerative diseases. Therefore, PPAR-γ agonists are thought to be neuroprotective in ALS and HD. We and others have
tested the neuroprotective eﬀect of pioglitazone (Actos), a PPAR-γ agonist, in G93A SOD1 transgenic mouse model of ALS and
found signiﬁcant increase in survival of G93A SOD1 mice. These ﬁndings suggest that PPAR-γ may be an important regulator of
neuroinﬂammation and possibly a new target for the development of therapeutic strategies for ALS. The involvement of PPAR-γ
in HD is currently under investigation, one study ﬁnds that the treatment with rosiglitazone had no protection in R6/2 transgenic
mouse model of HD. PPAR-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that works together with combination of
other transcription factors like PPAR-γ in the regulation of mitochondrial biogenesis. Therefore, PPAR-γ is a possible target for
ALS and HD as it functions as transcription factor that interacts with PGC-1α. In this review, the role of PPAR-γ in ALS and HD
is discussed based on the current literature and hypotheses.
Copyright © 2008 Mahmoud Kiaei. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors that belong to the nu-
clear hormone receptor superfamily which includes PPAR-
γ,P P A R - α, and PPAR-β/δ.P P A R - γ is the most studied re-
ceptor and has two isoforms produced due to alternative
splicing and alternate translation initiation: PPAR-γ1 and
PPAR-γ2 [1, 2]. Another ligand-activated transcription fac-
tor is retinoid-X receptor from the same superfamily that
forms heterodimeric complexes with PPARs in response to
ligand binding. These heterodimeric complexes bind to the
cis-acting sequences that are also called peroxisome prolifer-
ators response element (PPRE) on DNA to activate or inac-
tivate the transcription of target genes (for further details see
[3–5]).
PPARs are ligand-dependent transcription factors that
bind to speciﬁc PPREs and enhance the expression of reg-
ulated genes [6]. PPARs regulate the expression of target
genes, in particular those associated with lipid metabolism
[7–9]. PPAR isotypes appear to exhibit distinct patterns
of tissue distribution and diﬀer considerably in their lig-
and binding domains, implying that they possibly per-
form diﬀerent functions in diﬀerent cell types [2, 10–13].
PPAR-α is expressed in high levels in hepatocytes, entro-
cytes, and kidney [12]. PPAR-α is implicated to be respon-
sible for the peroxisome proliferator-induced pleiotropic re-
sponses [14]. PPAR-α and δ appear primarily to stimu-
late oxidative lipid metabolism, while PPAR-γ is princi-
pally involved in the cellular assimilation of lipids via an-
abolic pathways. Recently, other functions for PPAR-γ are
described, such as neuroprotection in ischemia [15] and its2 PPAR Research
eﬀect on spinal cord injury (SCI) [16]( a l s of o rr e v i e ws e e
[17]).
PPAR-γ h a sb e e nd e m o n s t r a t e dt ob ei n v o l v e di na d i p o -
genesis and diﬀerentiation, and its involvement in other tis-
sues speciﬁcally in central nervous system is rapidly emerg-
ing [16, 18–20]. PPAR-γ is shown to have a vital role in
adipocytediﬀerentiationbothinvivoandinvitro[1,21,22].
Recent studies demonstrate PPAR-γ agonists to prevent in-
ﬂammation and neuronal death after focal cerebral ischemia
in rodents [15, 23–25]. Thiazolidinediones (TZDs) are po-
tentsyntheticagonistsofPPAR-γ showntoinduceneuropro-
tection after cerebral ischemia by blocking inﬂammation. In
a recent study, pioglitazone and rosiglitazone (Figure 1(a))
treatment in SCI in adult rat signiﬁcantly decreased the le-
sion size, motor neuron loss, myelin loss, as well as as-
trogliosis and microglial activation due to SCI [16]. These
TZDs signiﬁcantly enhanced the motor function recovery af-
ter SCI. The beneﬁcial and protective lipid-independent ef-
fects of TZDs are the anti-inﬂammatory capacities of PPAR-
γ [4]. TZDs inhibit the expression of various inﬂammatory
proteins like inducible nitric oxide synthase (iNOS), tumor
necrosis factor-α (TNF-α), and matrix metalloproteinase-9
(MMP-9)inmacrophages[26]andarebeneﬁcialindisorders
such as inﬂammatory bowel disease [27]. These inﬂamma-
tory molecules are shown to be neurotoxic in models of neu-
rodegenerative diseases, for example, in ALS [28–30]. Sev-
eral anti-inﬂammatory mechanisms have been suggested, in-
cluding inhibition of nuclear factor kappa B (NF-κB), ac-
tivator protein-1 (AP-1), in addition to signal transducers
and activators of transcription (STAT) transcription factors
by PPAR-γ [31]. Although nuclear receptors repress target
genes in the absence of ligand by recruiting corepressors, the
molecular mechanism for transcriptional repression by nu-
clear receptors in response to the binding of ligands await
further research. It is possible that PPAR-γ is involved in
the reciprocal inhibition of diﬀerential transcription systems
through limited availability of shared cofactors. Recently, an
alternative mechanism suggested that a functionally distinct
pool of PPAR-γ is susceptible to ligand-dependent sumoyla-
tion (covalent attachment of small ubiquitin-like modiﬁer)
at lysine 365, leading to recruitment and stabilization of nu-
clear corepressor (N-CoR) complexes at the promoters of
proinﬂammatory genes thereby repressing them [32].
2. PPAR-γ AND AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a devastating fatal
neurodegenerative disorder characterized by a loss of up-
per and lower motor neurons. Oxidative stress, mitochon-
drial dysfunction, and neuroinﬂammation have been impli-
cated in ALS pathogenesis (Figure 1(b)). PPARs, in partic-
ular PPAR-γ, may be a major signaling pathway involved
in neuroinﬂammation in ALS. The activation or inactiva-
tion of PPAR-γ could provide a viable and promising ap-
proach to understand the mechanism of neuroinﬂammation
in ALS (Figure 1(b)). Since neuroinﬂammatory pathway has
become one of the hallmarks of ALS [29, 33, 34], therefore,
blockage of neuroinﬂammation is of great interest because of
the potential eﬃcacy in ALS patients. PPAR-γ has been iden-
tiﬁed as a key regulatory factor in the modulation of target
genes with PPAR response element (PPRE) in their promot-
ers, including those encoding for inﬂammation (iNOS, NF-
κB, COX-2), oxidative stress, and apoptosis. Synthetic PPAR-
γ agonists developed in the past 25 years that are used pri-
marily as antidiabetic drugs are suitable candidates and are
indispensable to study the role of PPAR-γ in ALS which may
potentially lead to beneﬁcial eﬀects in ALS patients.
Previous studies have shown the protective eﬀect of
PPAR-γ agonists in many experimental models such as in
experimental autoimmune encephalomyelitis (EAE) [35],
cytokine-induced apoptotic cell death of cerebellar granule
cells in vitro and in vivo, and against glutamate-induced cell
death in mixed cortical neurons and glia cocultures [36, 37].
Additionally, PPAR-γ agonists are reported to be neuro-
protective in tyrosine hydroxylase positive neurons in sub-
stantia nigra when exposed to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) [18, 19].
3. PIOGLITAZONE IS NEUROPROTECTIVE IN ALS
We have tested the neuroprotective eﬀect of pioglitazone in
transgenic G93A SOD1 mouse model of ALS and showed
that pioglitazone treatment improved motor performance,
delayed weight loss, attenuated motor neuron loss, and sig-
niﬁcantly increased survival by delaying the onset of ALS
[38]. Our results also show that pioglitazone treatment re-
duced microglial activation and gliosis in the spinal cord as
assessed by immunohistochemical staining for CD40 (mi-
croglia marker) and GFAP (astrocyte marker), respectively.
Furthermore, we showed that pioglitazone treatment re-
duced iNOS, NF-κB, and 3-nitotyrosine immunoreactivity
in the spinal cord of G93A transgenic mice.
Our ﬁndings were also conﬁrmed by another study on
the eﬀect of pioglitazone treatment in G93A SOD1 trans-
g e n i cm o u s em o d e lo fA L S[ 39]. In this study, PPAR-γ
agonist treatment improved survival, muscle strength, and
weightlossinALSmice.Quantiﬁcationofmotorneuronloss
was performed at 90 days of age where approximately 30% of
motor neurons were lost in G93A mice spinal cord. Pioglita-
zone treatment completely prevented this motor neuron loss
in the spinal cord of G93A mice. They also showed signiﬁ-
cant reduction in microglial activation as well as reduction
in the expression of COX-2 and iNOS [39].
Further evidence in the modulation of proinﬂammatory
markers by pioglitazone were reported by Sch¨ utz et al. which
suggests that mRNA levels of two cytokine suppressor genes,
suppressor of cytokine signaling 1 and 3 (SOCS-1 and -3),
were increased as assessed by semiquantitative RT-PCR [39].
OthershavereportedsimilarincreaseinSOCS-1and-3inre-
sponsetoTZDsinmicrogliaandastrocytesinvitro[40].The
increase in SOCS-1 and -3 is implicated with the inhibition
of Janus kinase-signal transducer and activator of transcrip-
tion(JAK-STAT)ininﬂammatorysignaltransduction.Other
studies using PPAR-γ agonists suggest that the mechanism of
actions are also by induction of neuroprotective genes such
as heat shock proteins [16]. Recently, Xu and Drew demon-
strated that PPAR-γ agonists suppress cytokines like IL-12
family in EAE, an experimental model of multiple sclerosis,Mahmoud Kiaei 3
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Figure 1: (a) Structure of PPAR agonists, (b) schematic diagrams linking mechanisms of neuronal cell death in ALS and a representation
of PPAR-γ activation. The mechanisms and pathways implicated in the pathogenesis of ALS that lead to the demise of motor neurons are
multiple. Activation of PPAR-γ by pioglitazone has the potential to block inﬂammatory pathway via the upregulation of anti-inﬂammatory
genes and downregulation of proinﬂammatory genes. The transcription of PPAR-γ target gene regulation occurs when ligand binds to
PPAR-γ and PPAR-γ-RXR heterodimers formed, then it binds to PPRE of DNA of target gene.
when treated with 15-d-PGJ2 and rosiglitazone [35]. These
studies provide evidence that PPAR-γ agonist responses are
originating from activated glial cells in central nervous sys-
tem. PPAR agonists are shown to modulate microglia and as-
trocytes in central nervous system diseases as these cells are
chronically activated and thought to contribute to neuroin-
ﬂammation with pathological abnormalities in degenerative
diseases [41]. Pioglitazone treatment in G93A mice showed
reduction in gliosis which is another experimental evidence
that PPAR-γ acts on glial cells in CNS [38]. The action of
PPAR-γ in neuronal cells needs to be studied.
The preliminary reports on the neuroprotective role of
PPAR-γ agonist in transgenic mouse model of ALS and other
experimental animal models could potentially be a foun-
dation for new series of studies to understand the mecha-
nism and molecular details of PPARs and their role in pro-
tecting motor neurons from inﬂammatory damages in ALS
(Figure 1(b)). The mechanisms of how PPAR-γ agonists in-
duce neuroprotection by blocking neuroinﬂammation is not
fully understood and further information on the molecular
details of PPAR-γ in neuroinﬂammatory pathways will pro-
vide crucial insights on the role of PPAR-γ in ALS and other
neurodegenerative diseases.
4. MITOCHONDRIAL DYSFUNCTION IN ALS
Mitochondrial compromise in ALS is substantiated by re-
ports of changes in their structure, number, and localization
in motor neurons and skeletal muscle, in familial and spo-
radic ALS patients [42]. Other studies reported the potential
involvement of mitochondria in the pathogenesis of ALS as
mitochondrial abnormalities were found in proximal axons,
anterior horn of ALS spinal cords [43]. Additionally, defects
in respiratory chain complexes have been detected in post-
mortemmuscleandspinalcordofALSpatients.Basedonthe
evidence of mitochondrial dysfunction in FALS-SOD1, it is4 PPAR Research
hypothesized that mutant SOD1 may directly damage mito-
chondrial function and integrity. Several studies have shown
thattransgenicmiceoverexpressing humanG93ASOD1that
display most of the ALS symptoms and pathologies have mi-
tochondrial dysfunction. More importantly, several studies
suggests that mitochondrial abnormalities occur long before
disease onset [44]. Kong and Xu found massive mitochon-
drial degeneration in motor neurons that are on the brink of
dyingandevenvacuolarandswollenmitochondriaarefound
near motor neuron cell debris in G93A mice [45]. These
observations suggest that mitochondrial abnormalities may
trigger the onset of ALS. Recently, we and others have shown
thatwildtypeandmutantSOD1arefoundwithinmitochon-
drion which was known to be a cytosolic enzyme [46, 47].
How SOD1 is interacting with mitochondria is unclear and
it is being actively investigated. The toxic action of mutant
SOD1 in and out of mitochondria could be partly explained
as follows. (i) Mutant but not wild type SOD1 binds to heat
shock proteins causing an inhibition of chaperon activities.
Both mutant and wild type SOD1 bind to antiapoptotic pro-
tein Bcl-2, on the outer mitochondrial membrane, blocking
its antiapoptotic activity [42]. (ii) The presence of mutant
SOD1 in the mitochondria leads to formation of SOD1 ag-
gregates, entrapping Bcl-2, blocking protein importation to
mitochondria which may trigger neuronal cell death due to
mitochondrial dysfunction [42].
SincePGC-1αisknowntocoordinatemitochondrialbio-
genesis and regulates mitochondrial function, it is possible
to predict that PGC-1α could play an important role in ALS.
Impairment of PGC-1α could contribute to mitochondrial
dysfunction in ALS. To date, there is no published data on
the role of PGC-1α or its expression in the transgenic mouse
model of ALS or human ALS postmortem tissues. However,
there are reports on the altered or impaired expression of
genesinALSthatsomeofthemﬁtinthePGC-1αtargetgenes
category [29, 48], suggesting that there may be a prominent
role for PGC-1α translational machinery in ALS.
Since PGC-1α is a PPAR-γ coactivator, it is possible that
PPAR-γ agonists may be able to activate PGC-1α and also the
PGC-1αtargetgenes.LikeinHD,areductionofPGC-1αand
itstargetgenesexpressionisattributedtomutanthuntingtin,
similarlymutantSOD1couldimpairPGC-1αandexpression
of its target genes in ALS. Whether mutant SOD1 can impair
PPAR-γ is yet to be determined. Future studies on PGC-1α
and PPAR-γ in ALS patients and transgenic mice will shed
some lights on these pathways in disease development.
5. PPAR-γ AND HUNTINGTON’S DISEASE
Huntington’s disease is an autosomal dominant, fatal neuro-
genetic disease that aﬀects approximately 1 in 10,000 peo-
ple [49]. The etiology of HD is shown to be the unstable
CAG repeat expansion in the huntingtin gene on chromo-
some 4 resulting in polyglutamine expansion in huntingtin
protein. The polyglutamine expansion causes the aggrega-
tion of huntingtin protein and formation of neuronal in-
clusion bodies as reviewed by Ortega et al. [50]. Mitochon-
drial dysfunction has been implicated in HD since defects
in electron transport chain complexes are evident in several
tissues from HD patients and transgenic mouse models of
HD [51–55]. The mechanisms for this mitochondrial dys-
function are actively been studied and in spite of some new
and novel discoveries and hypotheses, it is not fully under-
stood how mitochondrial dysfunction and oxidative stress
and expansion of unstable CAG repeats in huntingtin gene
cause HD. Recent reports show that mutant huntingtin in-
terferes with transcriptional PPAR-γ coactivator-1α (PGC-
1α) causing impairment on its function in HD, suggest-
ing that mutant huntingtin plays a role in the dysregula-
tion of PGC-1α-mediated transcription and activity, impair-
ing mitochondrial function, and leading to HD pathogen-
esis [56–58]. Weydt et al. found that PGC-1α target genes
(NDUFS3, CYCS, COX6A1, NDUFB5, ACADM, TFAM, and
LDHB) had reduced expression in HD patient and mouse
striatum [27]. They also found that HD mice brain mito-
chondria show reduced oxygen consumption rates. An in-
teresting ﬁnding was that the PGC-1α and uncoupling pro-
tein 1 (UCP-1) circuit was found to be disrupted in the
brown adipose tissue (BAT) of HD transgenic mice. This
was discovered when HD mice challenged with cold. As in
mammals, after cold is sensed in the hypothalamus, an in-
crease in sympathetic tone in the periphery ensues. In ro-
dents, BAT is the tissue that responds to cold. In HD and
wild type mice challenged with cold, PGC-1α expression in-
creased, but in HD mice UCP-1, expression was not up-
regulated. However, they showed that PGC-1α expression is
decreased in the striatum of human HD. They also exam-
ined the expression of unclear hormone receptors (PPAR-α,
RXR-α)andtranscriptionfactors(NRF-1)thatknowntorely
uponPGC-1αfortargetgeneactivation,thesegeneswereup-
regulated, suggesting possible compensatory upregulation of
PGC-1α-dependent transcription factors in human HD cau-
date. Weydt et al. study proposes that based on the evidence
for impaired energy production and/or impaired responses
to oxidative stress, evaluation of metabolic processes occur-
ring in nonneuronal tissues in the periphery may yield fac-
tors and pathways that contribute to neurodegenerative dis-
eases. Weydt et al. and Cui et al. studies provide further sup-
port that the reduction of PGC-1α and its target genes in HD
striatumarecausedbymutanthuntingtin.Weydtetal.stated
frompersonalcommunicationwithJ.BoatsandR.E.Hughes
that their yeast two-hybrid screen identiﬁed that PPAR-γ is
a huntingtin interactor, and the interaction was validated
for its biological signiﬁcance by demonstrating an eﬀect of
PPAR-γ dosage upon HD neurodegeneration in the ﬂy eye
[27].
I n c r e a s e dl e v e l so fi N O Si nH D[ 59], elevated oxida-
tive damage products such as malondialdehyde, 8-hydrox-
ydeoxyguanosine,3-nitrotyrosine,andhemeoxygenaseinar-
eas of degeneration in HD brain, and increased free radi-
cal production in animal models, indicate the involvement
of oxidative stress in HD [60]. This important pathway has
great promise and must be explored in order to understand
theroleofPPAR-γ andtoidentifynewtherapeutictargetsfor
HD.
Rosiglitazone (a PPAR-γ agonist) that induces sensitiza-
tion to insulin was tested in R6/2 transgenic mouse model
of HD for the treatment of atypical diabetes in these miceMahmoud Kiaei 5
[61]. The eﬀect of glibenclamide (a sulfonylurea) that depo-
larizes pancreatic beta cells by blocking ATP-sensitive potas-
sium channels to induce exocytosis of insulin leading to in-
crease in insulin levels was also tested in R6/2 mice. Chronic
treatmentwiththesetwodrugs,singlyorincombination,did
not change the course of diabetes or survival, weight loss of
R6/2 mice. In their paper, general characteristics of diabetes
in R6/2 mouse model of HD were described such as devel-
opment of glycosuria by the age of 9.3 weeks. They showed
that72%ofsurvivingR6/2micetestedpositiveforglycosuria
by 14 weeks of age. In this study, they found that R6/2 mice
displayed progressively worsening glucose intolerance. It is
perplexing that there was no correlation between the ages of
onset of glucosuria and the age at death of R6/2 mice and
R6/2 mice with glycosuria die at similar age as those R6/2
mice without it. They tested glibenclamide and rosiglitazone
in an acute treatment paradigm in R6/2 mice at 6 weeks and
10 weeks of age. Glibenclamide signiﬁcantly reduced blood
glucose concentrations in R6/2 mice and wild type mice just
one hour after challenge, while rosiglitazone did not alter
postchallengebloodglucosevaluesinolderR6/2miceorwild
type mice. However, the chronic daily treatment with rosigli-
tazone in combination with glibenclamide signiﬁcantly re-
duced the fasting blood glucose concentration in all mice at
10 weeks of age [61]. Although the objective of this study
was to examine the onset of diabetes and its possible con-
tribution to the mortality and motor impairment of R6/2
mice, it also provided data for the role of PPAR-γ in R6/2
mice. A recent study also reported the use of metformin, an-
other antidiabetes drug in R6/2 transgenic mice [62]. Met-
formin treatment in R6/2 mice had beneﬁcial eﬀect only in
males with lower doses (2mg/mL) which translate to about
300 mg/kg/day, and only increased survivals modestly while
the fasting daily glucose levels was not changed. Metformin
had no eﬀect in females and higher dose (5mg/mL) had
no eﬀect in males’ survivals while the glucose level was re-
ducedat12weeksofage.Metforminhasnumerouseﬀectson
metabolism, including insulin sensitization [63], increased
glucose uptake [64], decrease hepatic glucose synthesis [65],
activation of AMP-activated protein kinase (AMPK, an en-
zyme involved in glucose and fatty acid metabolism) [66],
and mitochondrial inhibition [67, 68]. Activation of AMPK
is associated with mitochondrial proliferation and biogene-
sis [69]. Rosiglitazone was used as PPAR-γ agonist in R6/2
mice, which could be used as the bases to test the role of
PPAR-γ in HD, glibenclamide and metformin were used to
treat atypical diabetes in R6/2 mice. Metformin treatment
in R6/2 mice increased brain AMPK phosphorylation [62]
although this needs to be conﬁrmed. Activation of AMPK
leads to reduction in ATP-consuming processes and facilitate
ATP-generating cellular processes which could be an expla-
nation for the metformin eﬀe c ti nR 6 / 2m a l e s .M e t f o r m i n
was also considered to be eﬀective in R6/2 mice because of its
ability to sensitize insulin which leads to facilitation of glu-
cose utilization. However, role of metformin in mitochon-
drial biogenesis in R6/2 mice was not examined. The pro-
tective eﬀect of metformin in R6/2 mice could be the syn-
ergistic eﬀect from several pathways including regulation of
PGC-1α activity through its direct activation of AMPA ki-
nase. Although the exact mechanism underlying mitochon-
drial biogenesis may vary between tissues, emerging data in-
dicatethatsubstantialoverlapexists.Metformindoesnotbe-
long to any class of PPAR-γ agonists although it is an antidi-
abetic for type-2 diabetes and stabilizes the glucose level.
PGC-1α has been implicated in mitochondrial biogen-
esis through its ability to control number of genes such as
nuclear respiratory factor-1,-2 (NRF-1,-2), estrogen related
receptor α (ERRα), and mitochondrial transcription factor A
(Tfam) [70]. Compounds like resveratrol have been impli-
cated in mitochondrial biogenesis [71]. Resveratrol has been
shown to activate sirtuin 1 (SIRT1) and results in PPAR-γ-
mediated transcriptional repression, inhibition of adipoge-
nesis, enhanced lipolysis, and the release of free fatty acids
[72].ActivatedSIRT1leadstodeactylationofPGC-1αresult-
ing in an activation of PGC-1α [73]. By deacetylating PGC-
1α, SIRT1 represses glycolysis, increase hepatic glucose out-
put, and modulates mitochondrial function and biogenesis
[73].
PGC-1α is known as master regulator of mitochondrial
biogenesis and is shown to modulate a number of metabol-
ically relevant transcription factors that collectively help in
mitochondrial biogenesis (for review see [61, 74]). Although
PPAR-γ agonist treatments in R6/2 failed, it is premature to
conclude that there is no role for PPARs in HD. Therefore,
further studies in other models of HD are required to exam-
ine other PPAR-γ agonists. Moreover, the eﬀect of PPAR-γ
agonists on the expression and activation of PGC-1α in cell
culture models of HD may provide preliminary data to plan
full-scale studies in animal models of HD. The rationale for
that is based on the increasing evidence that PGC-1α expres-
sion which is downregulated in patients with Huntington’s
disease and in several animal models of this neurodegenera-
tive disorder [70].
Thiazolidiones and rexinoids induce PGC-1α gene tran-
scription in brown and white adipocytes [75]. Since PCG-
1α shown to have roles in gluconeogenesis, fatty acid oxida-
tion,andadaptivethermoregulation,thenitcanbepredicted
that PPAR-γ agonists could help HD mice to maintain ther-
moregulatory function when exposed to cold. Based on the
studies on PGC-1α knockout mice that shown to have neu-
rodegenerative lesions, particularly in striatum, suggest that
PGC-1α may have an important function in neurons [76].
However, the neurodegenerative lesions in PGC-1α knock-
out mice do not mimic lesions in HD. The role of PPAR-γ in
ALS, AD, and Parkinson’s disease are backed with evidence
[19, 20, 38, 39] while the role of PPAR-γ in HD lacks crit-
ical evidence and needs to be studied further. Future stud-
ies in other transgenic mouse model of HD could shed light
on the role of PPARs in HD. Considering recent results on
thermoregulation and mitochondrial biogenesis impairment
in HD, and potential neuroprotective role of PGC-1α in HD,
PPAR-γ desperately seeking further attention and these types
of studies could provide essential data on the role of PPAR-γ
in HD.
It is possible that TZDs are also involved in mitochon-
drial biogenesis [77, 78]. Studies in patients treated with
PPAR-γ agonists indicate that the reduction of insulin re-
sistance is resulted from the activation of PPAR-γ [78].6 PPAR Research
PPAR-γ’snaturalcoactivatorisPGC-1α.TZDscanmimicthe
eﬀect of PGC-1α on PPAR-γ.I fP G C - 1 α levels reduces or be-
come inactivated by acetylation, then the activity of PPAR-γ
could be aﬀected.
6. FUTURE PERSPECTIVES
In this review, we highlighted the role of PPAR-γ in neurode-
generative diseases, in particular in a mouse model of ALS
and HD. The utilization of pioglitazone in a mouse model
of ALS by two independent studies provides strong indica-
tion for the involvement of PPAR-γ in ALS. Whether PPAR-
γ is involved in HD remains to be clariﬁed as one study
showed the treatment of R6/2 mice with rosiglitazone, an-
other PPAR-γ agonist, had no beneﬁcial eﬀect.
In the future, we will explore the mechanisms by which
PPAR-γ agonists produce neuroprotection in a mouse model
of ALS and test whether PPAR-γ has a role in HD. It would
be of great interest to determine whether the eﬀect of PPAR-
γ is powered by glial or neuronal cells or both in these mod-
els. It would also be of great interest to determine the eﬀect
of PPAR-γ agonist on muscles in ALS and HD mouse mod-
els. These studies in complement with in vitro cell culture
studies are necessary in determining the role of PPAR-γ in
ALS and HD. Since a thermoregulatory defect exists in HD
mouse models (for review see [70]), it would be very infor-
mative to test the eﬀect of PPAR-γ agonists on HD mouse
models for their eﬀect in thermoregulation. The activation
of PGC-1α in HD mouse models or overexpression of PGC-
1α in HD mouse models show eﬃcacy in blockage of neu-
ronal death, and lead to improvement in behavioral pheno-
types and increase in survival in several HD mouse models.
If these are conﬁrmed, then there is bonaﬁde evidence that
activation of PGC-1α could be a great therapeutic strategy
for HD. The lack of report on the role of PGC-1α in ALS
is a limiting step on the hypothesis that PGC-1α could be a
target of investigation or therapeutic for ALS. Mitochondria
have been implicated in ALS and PGC-1α has possible role
in mitochondrial biogenesis, therefore, it would be informa-
tive to examine mitochondrial abnormalities and PGC-1α in
ALS. However, since PPAR-γ agonist shown to activate PGC-
1α, therefore, there is an indirect possibility that PGC-1α in
connection with PPAR-γ could play some role in ALS.
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